Alopecia Areata: Current and Emerging Therapies.

Alopecia areata (AA) is a chronic immune-mediated disease characterized by non-scarring hair loss and a highly heterogeneous clinical course. Historically managed with nonspecific immunosuppressive therapies, AA has undergone a major therapeutic transformation driven by advances in the understanding of its immunopathogenesis, particularly the central role of interferon-γ, interleukin-15, and other cytokines that signal through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway as well as the development of JAK inhibitors. Targeted JAK inhibitors have emerged as the first reliably effective systemic treatments for severe AA, leading to the regulatory approval of baricitinib, ritlecitinib, and deuruxolitinib. Pivotal phase 3 trials have demonstrated clinically meaningful scalp hair regrowth with these agents, with responses often deepening over time under continuous therapy. Long-term extension studies and real-world data further support their effectiveness and manageable safety profiles in appropriately selected patients. Indirect comparative analyses suggest differences in short-term efficacy among approved JAK inhibitors, although the absence of head-to-head trials requires cautious interpretation. Beyond approved therapies, a robust pipeline bears hope that other immunomodulatory strategies can effectively address AA pathobiology. Pediatric development programs and real-world observational studies are also broadening the evidence base across age groups and clinical settings. Despite these advances, significant challenges remain. A substantial proportion of patients fail to achieve near-complete or complete regrowth, all approved medicines belong to the same drug class, and there are no agents approved for pre-adolescents. This review provides a critical overview of approved and emerging therapies for AA, integrating clinical trial data, comparative efficacy analyses, and real-world evidence, while highlighting current limitations and future directions.